Latest Content

CLL’s intrinsic immune dysfunction spans humoral, cellular, and innate defects, persisting even with targeted therapy.

Cancer trauma, drug pricing claims, abortion cost gaps, insurance denials affecting 1 in 5, and food insecurity's economic toll top this week's roundup.

FDA decisions in May 2026 included 5 major oncology approvals, including first-in-class therapies for breast cancer, AML, MCL, and NMIBC.

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Canopy remote therapeutic monitoring with ePROs cuts hospitalizations and extends time to discontinuation in metastatic cancer, saving millions.

Middle socioeconomic status (SES) elevates multimorbidity risk; healthy lifestyles mitigate this. Targeted interventions for middle-SES populations, especially middle-aged non-Hispanic White women, are crucial.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Men and urban minority patients with early-onset CRC face elevated CVD death risk, highlighting gaps in survivorship care and research, Meng-Han Tsai, PhD, said.

Three-year trial data show baricitinib sustains and deepens hair, eyebrow, and eyelash regrowth in severe alopecia areata, with stable long-term safety.